Elias Jabbour, MD

Articles

Relapsed/Refractory B-Cell ALL: Adopting MRD Testing into Routine Practice

February 15th 2022

The significance of having novel therapies and molecular tests available to help guide treatment decisions for patients with B-cell acute lymphoblastic leukemia, and recommendations on how to increase the uptake of MRD testing into routine clinical practice.

MRD Assessments in B-Cell ALL

February 15th 2022

When to test for measurable residual disease in B-cell acute lymphoblastic leukemia, and what to keep in mind when selecting a testing method to help assess MRD.

Emerging Novel Therapies for Relapsed/Refractory B-Cell ALL

February 8th 2022

Emerging therapies in the clinical pipeline for relapsed/refractory B-cell acute lymphoblastic leukemia, as presented at ASH 2021.

Relapsed/Refractory B-Cell ALL: CAR-T Safety Profiles

February 8th 2022

An overview of adverse events commonly associated with CAR T-cell therapies in relapsed/refractory B-cell acute lymphoblastic leukemia.

CAR-T Therapy for Relapsed/Refractory B-Cell ALL: Sequencing Decisions

February 1st 2022

Recommendations for sequencing CAR T-cell therapies and other key therapies in patients with B-cell acute lymphoblastic leukemia.

CAR T Therapy for Relapsed/Refractory B-Cell ALL: Selecting Appropriate Patients

February 1st 2022

Implications of the ZUMA-3 clinical trial of anti-CD19 CAR T-cell therapy for adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Relapsed Refractory B-Cell ALL: Treatment Overview

January 25th 2022

The treatment approaches available for patients with B-cell acute lymphoblastic leukemia, and reactions to the availability of novel CAR T therapies for relapsed/refractory disease.

Relapsed Refractory B-Cell ALL: Patient Prognosis

January 25th 2022

Background information regarding the manifestation and prognosis of relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr. Jabbour on the Rationale to Evaluate KO-539 in Relapsed/Refractory AML

January 29th 2021

Elias Jabbour, MD, discusses the rationale to evaluate KO-539 in relapsed/refractory acute myeloid leukemia.

Dr. Jabbour on Selecting Ponatinib After Second-Generation TKI Failure in CML

January 19th 2021

Elias Jabbour, MD, discusses selecting ponatinib after failure of a second-generation TKI therapy in chronic myeloid leukemia.

Dr. Jabbour on the ASCEMBL Data With Asciminib in Chronic-Phase CML

December 17th 2020

Elias Jabbour, MD, discusses data with asciminib in patients with chronic-phase chronic myeloid leukemia.

Dr. Jabbour Discusses Recent Advancements in ALL

August 23rd 2018

Elias Jabbour, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses recent advances in the treatment of patients with acute lymphoblastic leukemia.

Dr. Jabbour Discusses Blinatumomab in ALL

August 2nd 2018

Elias Jabbour, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses blinatumomab (Blincyto) in acute lymphoblastic leukemia.

Dr. Jabbour on Emerging Subsets in ALL

October 29th 2016

Elias Jabbour, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses recent treatment advances and emerging subsets in acute lymphoblastic leukemia (ALL).

Dr. Elias Jabbour on Blinatumomab for ALL

May 31st 2016

Elias Jabbour, MD, associate professor, department of leukemia, division of cancer medicine, the University of Texas MD Anderson Cancer Center, discusses blinatumomab (Blincyto) for acute lymphocytic leukemia (ALL).

Dr. Jabbour on Front-Line Treatments for CML

March 15th 2011

Elias Jabbour, MD, Assistant Professor, Dept. of Leukemia, The University of Texas MD Anderson Cancer Center, discusses front-line treatments for CML, at the 2010 ASCO Annual Meeting.

Dr. Jabbour on Second-Generation TKIs in CML

March 15th 2011

Elias Jabbour, MD, Assistant Professor, Dept. of Leukemia, The University of Texas MD Anderson Cancer Center, on second-generation TKIs for patients with CML, a cancer that starts inside bone marrow.